Risk factor
Very poor trading liquidity
Profitability factor
Favourable analyst view
About
Taiwan Biomaterial Co., Ltd., established in 2010 and based in Zhubei, Taiwan, focuses on the innovation, development, and commercialization of medical devices throughout Taiwan. Their product offerings include Foamagen, a pioneering dural substitute characterized by its foamy structure. The company also provides a sophisticated negative pressure catheter system engineered for stroke intervention, which efficiently suctions and removes cerebrovascular embolism blood clots, accompanied by a specialized nickel-titanium guidewire essential for guiding intricate neurovascular procedures. Additionally, Taiwan Biomaterial develops advanced tissue repair and regeneration solutions specifically targeting the treatment of early-stage osteoarthritis.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Target Price
The average target price of 6649.TWO is 173 and suggests 357% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in